Core Viewpoint - The company is facing legal proceedings initiated by Cedar Wealth Management SPC, which has resulted in a court order for asset preservation affecting its bank account in China, with a cash balance of approximately RMB 2.55 million, until November 30, 2026 [1][2]. Group 1: Legal Proceedings - The court issued a notification on December 24, 2025, regarding the asset preservation order based on Cedar Wealth's arbitration application submitted on August 11, 2025 [1]. - Cedar Wealth claims that the company owes them approximately USD 2.05 million in unpaid service fees and other expenses, along with interest and legal fees totaling around RMB 1.04 million [2]. - The company has not received any invoices or requests for payment prior to the arbitration application, and is actively seeking more information from Cedar Wealth to understand the claims [2]. Group 2: Company Response - The board of directors is consulting legal advisors regarding the legal proceedings and arbitration, and is monitoring the potential legal, operational, and financial impacts on the company [2]. - As of the announcement date, the board believes that the legal proceedings and asset preservation order have not significantly adversely affected the company's overall business, operations, or cash flow [2]. - The company intends to negotiate with Cedar Wealth to explore possible settlement options to resolve misunderstandings and potentially terminate the legal proceedings and asset preservation order [3].

在仲裁申请中，Cedar Wealth提出以下申索： (a) 公司向Cedar Wealth支付的款项包括：(i)未偿还服务费 及其他支出达205万美元; (ii)按全国银行间同业拆借中心公布的一年期贷款最优惠利率计算据称未偿还 费用所产生的利息;及(iii)法律费用及资产保全保险费用合共约人民币104万元; (b) 拨康视云广州就支付 该等申索金额承担连带责任;及 (c) 仲裁程序费用将由被告承担。 由于被告于仲裁申请送达日期前未收到任何发票、费用通知或据称未偿还费用的要求，集团已积极与 Cedar Wealth保持联络，以收集有关引起该等申索的必要资料及详情。然而，截至本公告日期， Cedar Wealth尚未向集团提供更多详情，因此董事会认为于集团于2026年1月6日收到法院通知前，尚无有关仲 裁程序的足够资料以评估仲裁程序的性质及潜在影响与后果。 智通财经APP讯，拨康视云-B(02592)发布公告，于2026年1月6日，拨康视云生物医药科技(广州)有限公 司(根据中华人民共和国法律注册成立的公司间接全资附属公司)收到由广州市黄埔区人民法院签发日期 为2025年12月24日的通知。 法院应Cedar ...

香港交易及結算所有限公司及香港聯合交易所有限公司（「聯交所」）對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因 倚賴該等內容而引致的任何損失承擔任何責任。 CLOUDBREAK PHARMA INC. 撥康視雲製藥有限公司 * （於開曼群島註冊成立的有限公司） （股份代號：2592） 有關 針對一間附屬公司的法律程序 本公司董事會（「董事會」）謹此通知本公司股東及潛在投資者，於2026年1月6日，撥康視雲生物醫藥 科技（廣州）有限公司（「撥康視雲廣州」）（根據中華人民共和國（「中國」）法律註冊成立的本公司間接 全資附屬公司）收到由廣州市黃埔區人民法院（「法院」）簽發日期為2025年12月24日的通知（「法院通 知」）。 誠如法院通知所述，法院應Cedar Wealth Management SPC（「Cedar Wealth」）的申請，透過法律程序 （「法律程序」）作出裁定，對撥康視雲廣州在中國工商銀行開設的銀行賬戶（包括截至法院通知日期賬 戶內現金結餘約人民幣255萬元）實施司法保全至2026年11月30日止（「資產保全令」）。 1 經諮詢 ...

Market Overview - The Hong Kong stock market opened lower on January 7, with the Hang Seng Index down 1.01% at 26,439.68 points, the Hang Seng Tech Index down 1.65% at 5,729.41 points, the National Enterprises Index down 1.11% at 9,141.25 points, and the Red Chip Index down 0.64% at 4,114.5 points [1] - Major technology stocks experienced declines, with Alibaba down 4.05%, Tencent down 1.98%, JD.com down 1.47%, Xiaomi down 1.34%, NetEase down 2.18%, Meituan down 2.17%, Kuaishou down 2.78%, and Bilibili down 3.54% [1] - The biopharmaceutical sector continued to rise, with Kangfang Biopharmaceutical up over 6% [1] - The metals sector showed strength, with Luoyang Molybdenum up over 5% [1] - Oil stocks weakened, with PetroChina down over 3% [1] - Automotive stocks faced significant declines, with NIO down over 3% [1] Company News - Yadea Holdings (01585.HK) expects a net profit of no less than RMB 2.9 billion for 2025, up from RMB 1.27 billion in the previous year, driven by increased sales of electric two-wheelers and optimized product structure [2] - Poly Property Group (00119.HK) anticipates a cumulative contract sales amount of approximately RMB 50.2 billion for 2025, a decrease of 7.38% year-on-year [3] - Sunac China (01918.HK) expects a cumulative contract sales amount of approximately RMB 36.84 billion for 2025, down 21.85% year-on-year [4] - Gemdale Corporation (00535.HK) projects a cumulative contract sales total of approximately RMB 10.696 billion for 2025, a decrease of 47.33% year-on-year [5] - Greentown Management Holdings (09979.HK) estimates new project management fees for 2025 to be RMB 9.35 billion, an increase of approximately 0.4% [6] - Yuexiu Property (00123.HK) acquired a land parcel in Shanghai's Pudong New Area for RMB 2.561 billion [7] - Jiufang Zhitu Holdings (09636.HK) completed the acquisition of 100% equity in JF Financial and its core information system [8] - Weimob Group (02013.HK) partnered with Taobao Flash Sale to enhance local retail solutions [8] - Dali Pu Holdings (01921.HK) became a qualified supplier for Saudi Aramco [9] - Xiehe New Energy (00182.HK) successfully completed a secondary listing on the Singapore Stock Exchange [10] - Bokan Vision Cloud-B (02592.HK) submitted a clinical trial application for the new drug CBT-009 [11] - Yingtong Holdings (06883.HK) established a partnership with the Italian high-end fragrance brand CULTI to strengthen its distribution network in China [11] Institutional Insights - Guosen Securities believes that the Hong Kong stock market's recovery has begun, driven by a weaker US dollar and improved domestic liquidity, suggesting a focus on AI and PPI [12] - CITIC Securities anticipates a second round of valuation recovery and performance revival in the Hong Kong market in 2026, recommending attention to technology, healthcare, resource products, essential consumer goods, paper, and aviation sectors [12] - Everbright Securities notes that domestic policy support and a weaker dollar may lead to continued upward movement in the Hong Kong market, highlighting the relative strength of overall profitability [12] - Dongwu Securities indicates that the Hong Kong market is entering a period of upward volatility, emphasizing the importance of dividends and technology growth in the first half of the year [12] - Industrial Securities recommends a bullish stance, predicting a spring rally led by the Hang Seng Tech Index, with a continued bull market expected in 2026 [13]

Major Events - Brain动极光-B (06681) signed important business cooperation agreements with Peking University Sixth Hospital and Shandong Mental Health Center [1] - Cohere New Energy (00182) successfully completed a secondary listing on the Singapore Stock Exchange [1] - Bole康视云-B (02592) submitted a clinical trial application for the new drug CBT-009 to the Drug Evaluation Center [1] - Yingtong Holdings (06883) established a partnership with the Italian high-end fragrance brand CULTI to strengthen its high-end fragrance distribution network in China [1] - Weimeng Group (02013) initiated a business cooperation with Taobao Flash Purchase [1] - Dali普控股 (01921) officially became a qualified supplier for Saudi Aramco [1] - Yiming Anke-B (01541) regained global rights for IMM2510 and IMM27M [1] - Yuexiu Property (00123) subsidiary Shanghai Yuheng won a land parcel in Shanghai's Pudong New District [1] Operating Performance - Jinxin Reproductive (01951) reported a further narrowing of the overall decline in IVF egg retrieval cycles to -1.4% for 2025 [1] - Poly Real Estate Group (00119) achieved a cumulative contract sales amount of approximately 50.2 billion yuan for 2025, a year-on-year decrease of 7.38% [1] - Yadea Holdings (01585) issued a profit warning, expecting annual net profit to be no less than 2.9 billion yuan [1] - Jindi Commercial Real Estate (00535) reported a cumulative contract sales total of approximately 10.696 billion yuan for 2025, a year-on-year decrease of 47.33% [1] - Greentown Management Holdings (09979) estimated the construction fee for newly developed projects in 2025 to be 9.35 billion yuan, a year-on-year increase of approximately 0.4% [1] - Sunac China (01918) achieved a cumulative contract sales amount of approximately 36.84 billion yuan for 2025, a year-on-year decrease of 21.85% [1]

智通財經APP訊，撥康視雲-B(02592)發佈公告，本公司於美利堅合衆國(美國)特拉華州註冊成立的全資 附屬公司 ADS Therapeutics LLC (ADS USA)已成功向中國國家藥品監督管理局(國家藥監局)的藥品審評 中心(藥審中心)提交本集團核心產品之一CBT-009的新藥臨牀試驗申請。 CBT-009是一種由本集團獨立開發的新型、非水性阿托品眼用製劑，用於治療5至19歲兒童及青少年的 青少年近視。與現有水性阿托品滴眼液相比，CBT-009顯著提升製劑穩定性，可在室溫下長期儲存且無 需添加防腐劑，大幅改善患者用藥依從性與使用體驗。 本公司認爲，成功向藥審中心提交新藥臨牀試驗申請，標誌着CBT-009在中國臨牀開發的重要里程碑， 爲集團在該重要市場推進第三期臨牀試驗奠定堅實基礎。本集團將持續密切關注藥審中心的審評進度， 並於適時另行刊發公告，以知會本公司股東及潛在投資者相關最新發展。 该信息由智通财经网提供 ...

Core Viewpoint - The company has successfully submitted a new drug clinical trial application for its core product CBT-009 to the National Medical Products Administration of China, marking a significant milestone in its clinical development in the Chinese market [1] Group 1: Product Development - CBT-009 is a novel, non-aqueous atropine eye formulation developed independently by the company, aimed at treating myopia in children and adolescents aged 5 to 19 [1] - Compared to existing aqueous atropine eye drops, CBT-009 significantly enhances formulation stability, allowing for long-term storage at room temperature without the need for preservatives, thereby improving patient compliance and experience [1] Group 2: Regulatory Progress - The successful submission of the new drug clinical trial application is seen as a solid foundation for advancing the third phase of clinical trials in the important Chinese market [1] - The company will continue to closely monitor the review progress by the drug review center and will issue further announcements to inform shareholders and potential investors of relevant developments [1]

相关事件 拨康视云-B(02592.HK)：成功向药品审评中心提交CBT-009新药临床试验申请 拨康视云-B(02592.HK)单 一最大股东之一Water Lily自愿延长禁售期 格隆汇1月6日丨拨康视云-B(02592.HK)发布公告，公司于美国特拉华州注册成立的全资附属公司ADS Therapeutics LLC ("ADS USA")已成功向中国国家药品监督管理局("国家药监局")的药品审评中心("药审 中心")提交集团核心产品之一CBT-009的新药临床试验申请("新药临床试验申请")。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司（「聯交所」）對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因 倚賴該等內容而引致的任何損失承擔任何責任。 CLOUDBREAK PHARMA INC. 撥康視雲製藥有限公司 * CBT-009是一種由本集團獨立開發的新型、非水性阿托品眼用製劑，用於治療5至19歲兒童及青少年 的青少年近視。與現有水性阿托品滴眼液相比，CBT-009顯著提升製劑穩定性，可在室溫下長期儲 存且無需添加防腐劑，大幅改善患者用藥依從性與使用體驗。 （於開曼群島註冊成立的有限公司） （股份代號：2592） 自願公告 業務最新進展 成功向藥品審評中心提交CBT-009新藥臨床試驗申請 本公告乃由撥康視雲製藥有限公司（「本公司」，連同其附屬公司，統稱「本集團」）自願作出，以知會 本公司股東及潛在投資者有關本集團的最新業務發展。 本公司董事會（「董事會」）宣佈，本公司於美利堅合眾國（「美國」）特拉華州註冊成立之全資附屬公司 ADS Therapeutics LLC （「ADS USA」）已成功向中國國家藥品監督管理局（「國家藥 ...

拨康视云公告，于2026年1月1日，公司已收到基石投资者之一富策控股有限公司出具的自愿承诺函件， 据此，富策控股已自愿向公司承诺，就其根据相关基石投资协议认购的发售股份(包括任何可转换、可 兑换或可行使为或代表有权收取任何上述证券的任何证券)延长禁售承诺，延长期限自原禁售期届满之 翌日(即2026年1月3日)(包括当日)起至上述日期起6个月届满之日止(即2026年7月2日)，或公司与富策控 股另行协定的较早日期止。 智通财经APP获悉，香港联交所最新资料显示，1月5日，拨康视云-B(02592)股东将股票存入中信证券经 纪香港，存仓市值2.66亿港元，占比6.93%。 ...